title: Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
abstract: OBJECTIVE
  To characterize the pharmacokinetics of a single 500 mg oral dose of famciclovir in subjects with varying degrees of renal impairment.
  
  
  METHODS
  Twenty-seven subjects were enrolled in an open-label parallel-group study. Eighteen patients had renal impairment (average age [ +/- SD], 49 +/- 12 years), and nine subjects were healthy volunteers (average age, 28 +/- 7 years). Patients with renal impairment were stratified into groups based on estimated creatinine clearance (CLCR): mild impairment (CLCR, 60 to 80 ml/min/1.73 m2), moderate impairment (CLCR, 30 to 59 ml/min/1.73 m2) and severe impairment (CLCR, 5 to 29 ml/min/1.73 m2). Plasma and urine specimens were analyzed for concentrations of penciclovir, the antivirally active metabolite of famciclovir, by reverse-phase HPLC. Plasma data were analyzed with use of model-independent methods.
  
  
  RESULTS
  In subjects with normal renal function (CLCR > 80), the mean maximum plasma concentrations of penciclovir was 2.83 micrograms/ml (range, 1.30 to 3.82 micrograms/ml) and the mean time to reach maximum concentration was 0.89 hours (range, 1/2 to 1 1/2 hours). The mean apparent terminal elimination half-life was 2.15 hours (range, 1.56 to 2.87 hours). A linear relationship was observed between the plasma elimination rate constant and CLCR and between renal clearance and CLCR. Mean area under the plasma concentration-time curve from zero to infinity was approximately tenfold higher and the plasma elimination rate constant was approximately fourfold lower in patients with severe renal impairment than in subjects with normal renal function.
  
  
  CONCLUSIONS
  Consideration should be given to modification of the dosing schedule of famciclovir from the usual 8-hour interval to a 12-hour interval for patients with moderate renal impairment (CLCR 30 to 59 ml/min/1.73 m2) or a 24-hour interval for patients with severe renal impairment (CLCR < 30 ml/min/1.73 m2).
authors.affiliation: Department of Clinical Pharmacology, SmithKline Beecham Pharmaceuticals, Philadelphia, PA.
authors.forename: S C
authors.initials: SC
authors.lastname: Boike
authors.forename: M A
authors.initials: MA
authors.lastname: Pue
authors.forename: M I
authors.initials: MI
authors.lastname: Freed
authors.forename: P R
authors.initials: PR
authors.lastname: Audet
authors.forename: A
authors.initials: A
authors.lastname: Fairless
authors.forename: B E
authors.initials: BE
authors.lastname: Ilson
authors.forename: N
authors.initials: N
authors.lastname: Zariffa
authors.forename: D K
authors.initials: DK
authors.lastname: Jorkasky
mesh_terms: D015075:2-Aminopurine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002851:Chromatography, High Pressure Liquid; D003404:Creatinine / Q000097:blood / Q000652:urine; D000077595:Famciclovir; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011355:Prodrugs / Q000493:pharmacokinetics*; D012044:Regression Analysis
chemical_list: D011355:Prodrugs; D015075:2-Aminopurine; D003404:Creatinine; D000077595:Famciclovir